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Background: Chronic kidney disease (CKD) is increasing being recognized as a global public health problem.
However, there is dearth of information on the prevalence, determinants, and management of CKD from low- and
middle-income countries. The objectives of the study were to determine the 1) prevalence of CKD; 2) socio-demographic
and clinical factors associated with CKD; and 3) the existing management of these patients with regards to
blood pressure control, and use of antihypertensive medications.
Methods: We conducted a cross-sectional study on 2873 participants aged ≥40 years in 12 representative
communities in Karachi, Pakistan. The primary outcome was clinically significant CKD defined as estimated glomerular
filtration rate (eGFR) <60 mL/min/1.73 m2 estimated by CKD-EPI (CKD Epidemiology Collaboration) Pakistan equation
(0.686 × CKD-EPI1.059) or urinary albumin to creatinine ratio ≥3 mg/mmol (i.e. KDOQI CKD stage G3, A2 or worse).
Results: The overall prevalence (95% CI) of CKD was 12.5% (11.4 – 13.8%). The factors independently associated with
CKD were older age, hypertension, diabetes, elevated systolic blood pressure, raised fasting plasma glucose, raised
triglycerides, and history of stroke (p < 0.05 for each). About 267 (74.4%, 69.5 – 78.8%) adults with CKD had concomitant
hypertension. Of these, 130 (48.7%, 42.6 – 54.9%) were on antihypertensive medications, and less than 20% had
their BP controlled to conventional target of ≤140/90 mm Hg, and only 16.9% (12.6 – 21.9%) were on blockers of
renin-angiotensin system alone or in combination with other drugs.
Conclusions: Clinically significant CKD is common among Pakistani adults. The conventional risk factors for CKD
and poor control of blood pressure among patients with CKD highlight the need to integrate CKD prevention and
management in the primary care infrastructure in Pakistan, and possibly neighbouring countries.
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Chronic kidney disease (CKD) is increasing being rec-
ognized as a major public health problem globally [1].
The adverse outcomes associated with CKD including
kidney failure, accelerated cardiovascular disease (CVD),
and premature mortality have greater societal and eco-
nomical impact in low- and middle-income countries
[2]. A glomerular filtration rate (GFR) level of less than
60 ml/min/1.73 m2 (GFR stages G3a – G5), indicating* Correspondence: tazeen.jafar@duke-nus.edu.sg
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unless otherwise stated.CKD represents loss of half or more of the adult level of
normal kidney function, the level below which the risk
of adverse outcomes has been shown to increase. As
demonstrated in a large meta-analysis of a large general-
population cohort of 105,872 participants, albuminuria is
an independent marker of increase CVD mortality [3].
The Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guidelines 2012 for the
Evaluation and Management of Chronic Kidney Disease
classify CKD based on eGFR stages (G1 through G5 using
eGFR thresholds (G3 split G3a and G3b using eGFR
threshold of 45 ml/min/1.73 m2), and albuminuria
stages (A1 (<3 mg/mmol), A2 (3 to 30 mg/mmol) and
A3 (>30 mg/mmol)). The guidelines also recommendLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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methods for estimating GFR where available [4].
The burden of CKD may be further exaggerated in
rapidly urbanizing South Asian country like Pakistan
where a substantial proportion of 180 million are predis-
posed to chronic diseases including diabetes and hyper-
tension by virtue of low birth weight possibly associated
with reduced renal reserve [5]. Moreover, South Asian
countries are undergoing an epidemiological transition
with an increase in risk factors of CKD, and conse-
quently posing a burden on health systems [6]. Further-
more, CKD is also known to progress fast in Asians
compared to Western counterparts underscoring the
need for prevention through early detection and man-
agement of risk factors [7]. However, there is dearth of
representative data on the prevalence and determinants
of CKD from South Asian countries including Pakistan.
Furthermore, despite publications of clear guidelines
regarding the importance of blood pressure (BP), control
and trials demonstrating effectiveness of blockers of
renin-angiotensin system in patients with CKD, it is not
known how these patients are managed in low- and
middle-income countries that have traditionally diverted
resources for treating acute infectious diseases [8,9].
The objectives of this study were to determine the 1)
prevalence of CKD stage G3, A2 or worse; 2) socio-
demographic and clinical factors associated with CKD;
and 3) the existing management of patients with CKD
with regards to BP control, and use of antihypertensive
medications among adults in Karachi, Pakistan.
Methods
Study setting
This was a cross-sectional study representative of urban
city of Karachi, Pakistan, conducted as part of baseline
within a factorial design cluster randomized controlled
trial [10]. In brief, the Federal Bureau of Statistics has
divided the city of Karachi, the most populous city in
Pakistan with 18 million inhabitants, into 5000 clusters
each of about 250 households each. A multistage ran-
dom sampling was employed to identify 12 of 4200 low
to middle income (mean household monthly income
$70) clusters (Additional file 1: Figure S1). All adults
aged ≥ 40 years in these households were invited and the
written informed consent was obtained from all study
participants. Ethical approval was obtained from the Aga
Khan University Ethics Review Committee.
Screening
Trained research staff visited all households in each of
the 12 clusters, and informed consent was obtained for
screening from all eligible adults; who then underwent
for measurement of BP three times. The study was con-
ducted over one year during 2004 – 2005.A routine physical examination was performed and
the following information collected: (i) smoking status,
food frequency and physical activity (IPAQ, international
physical activity questionnaire), co-morbidities (history
of stroke, cardiovascular disease, known diabetes, known
hypertension); (ii) anthropometry (height, weight and
waist circumference); (iii) BP was measured thrice with a
calibrated automated device (Omron HEM-737 Intelli-
Sense; Omron Healthcare Inc., Vernon Hills, IL) in the
sitting position after 5 minutes of rest. If BP was ele-
vated (systolic blood pressure (SBP) ≥140 mm Hg or
diastolic blood pressure (DBP) ≥ 90 mm Hg) based on
mean of last 2 of 3 readings, subjects were visited again
after 1 – 4 weeks for re-measurement of BP to confirm
hypertension status if BP were persistently elevated,
and (iv) Blood specimens for glucose, creatinine and
lipids profile were collected in the morning after an
overnight fast of about 10 – 12 hours. For urine microal-
bumin and creatinine, first morning sample was collected.
All samples were transported in about one hour to the
clinical laboratory at the Aga Khan University Hospital
where samples were processed and stored at 2 – 8°C for
appropriate tests performed within 24 hours. Serum
creatinine and fasting blood glucose were measured on
Synchron Cx-7/Delta; Beckman Coulter, Fullerton, CA;
the lipid profile was measured on Hitachi-912; Roche,
Basel, Switzerland. Urine microalbumin and creatinine
were measured using nephelometry by the Array Systems
method on a Beckman Coulter and Synchron Cx-7/Delta.
All tests were performed to a standard protocol that
confirmed to the international standards for definitions
and measurements.
Serum creatinine measurements were calibrated at the
Cleveland Clinic laboratory-reference laboratory, where
serum creatinine levels were measured again using the
Roche enzymatic creatinine assay (in duplicate) which is
traceable to the National Institute of Standards and Tech-
nology creatinine reference measurement [11].Variable definitions
Glomerular Filtration Rate (GFR) was estimated using the
CKD-EPI (CKD Epidemiology Collaboration) Pakistan
(CKD-EPIPK) equation, a modified version of CKD-EPI
creatinine equation with a correction factor (0.686 × CKD-
EPI1.059) for South Asians (estimated GFR (eGFR) based
on this equation denoted as eGFRCKD-EPI(PK)) [11].
Hypertension was defined as persistent elevation of
SBP ≥140 mm Hg or DBP ≥90 mm Hg on the basis of
average of last two of three readings measured 5 minutes
apart at each visit, on two separate occasions, or taking
antihypertensive medications.
Diabetes was defined as fasting blood glucose ≥7.0 mmol/L,
or taking anti-diabetic medications.
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eGFRCKD-EPI(PK) < 60 mL/min/1.73 m
2 (reduced eGFR) or
urinary albumin to creatinine ratio (UACR) ≥3 mg/mmol
(albuminuria) based on a single spot urine sample.
Statistical analysis
The analyses were performed in IBM SPSS v20 and Stata
release 12.1 statistical software. The descriptive statistics
were performed on 2873 participants by CKD status.
Differences in means and proportions were assessed by
t-test and chi-square test respectively. The distribution
of eGFR in men and women was assessed graphically by
plotting median, 25th and 75th percentiles respectively
using quantile regression. The crude and age-standardized
prevalence (95% CI) of CKD was computed. The refer-
ence population for the latter was WHO (World Health
Organization) World Standard Population [12].
The final sample size for multivariable models was
2823 because of missing information on hypertension
status on 50 subjects (Additional file 2: Figure S2). Two
multivariable models were built for primary outcome
of CKD by stepwise logistic regression analysis using
forward selection procedure with an entry criteria of
p = 0.05 and removal criteria p = 0.20. The first model
was based on socio-demographic determinants (age,
sex, education, tobacco use, and physical activity), and
the second model was based on socio-demographic
plus clinical predictors, i.e. hypertension, diabetes,
self-reported history of coronary heart disease, self-
reported history of stroke, body mass index (BMI),
fasting plasma glucose, serum cholesterol, high density
lipoprotein cholesterol (HDL), low density lipoprotein
cholesterol (LDL), and serum triglycerides. Both the
multivariable models developed using stepwise logistic
regression were adjusted for clustering; and furthermore,
second model was also adjusted for co-morbidities, i.e.
history of coronary heart disease and history of stroke.
Moreover, all CKD patients with hypertension were
also assessed for 1) control of BP to levels ≤ 130/80 mm
Hg, and ≤140 /90 mm Hg, and 2) use of anti-hypertensive
medications by UACR status, i.e. UACR <3 mg/mmol
and ≥3 mg/mmol, respectively. For these analyses, KDIGO
2012 Clinical Practice Guideline based disease-specific
definition of hypertension in CKD (BP >140/90 or
BP >130/80 mm Hg for those with UACR <3 mg/mmol
and ≥3 mg/mmol, respectively) was used [8]. The use
of antihypertensive medications by drug classes was
assessed. Single drugs used alone represented mono-
therapy and counted as individual drug; whereas two or
more single drugs taken together either separately or as
fixed dose combination drugs were counted under com-
bination category (and not in the individual drug cat-
egories). The p-value <0.05 was considered statistically
significant.Results
A total of 3143 adults were aged 40 years or older in
the 12 communities, and were invited for blood and
urine tests; these measurements were available on 2873
(91.4%) individuals. The baseline characteristics of the
population with and without CKD are shown in Table 1.
Moreover, the baseline characteristics according to
eGFR and UACR categories are shown in the Additional
file 3: Tables S1 and S2.
Missing information
Information on serum creatinine and UACR measure-
ments was missing in 261 (8.3%), and 253 (8.0%) partici-
pants respectively. The characteristics of subjects with
(n = 270) and without missing information on CKD (n =
2873) (i.e. serum creatinine and/or UACR) did not differ
by age (51.5 vs. 52.6 years, p = 0.14), gender (men, 48 vs.
48%, p = 0.99), SBP (137 vs. 137 mm Hg, p = 0.576) or
history of stroke (3.1 vs. 3.7%, p = 0.563). However, mean
BMI (25.8 vs. 24.1 Kg/m2, p < 0.001), mean DBP (86 vs.
84 mm Hg, p = 0.024) or proportion of hypertension
(44.9 vs. 32.9%, p < 0.001) was higher among subjects
with available CKD information compared to those with
missing information. An additional 50 individuals did
not have hypertension status confirmed. A comparison
of the above-mentioned characteristics with the individ-
uals with complete information (n = 2,823) did not show
any significant difference with respect to age, gender,
SBP, DBP, or stroke.
CKD prevalence
The distribution of eGFR among adult men and women
is illustrated in Figure 1. The crude prevalence (95% CI) of
reduced eGFR (eGFRCKD-EPI(PK) <60.0 mL/min/1.73 m
2),
albuminuria (UACR ≥3 mg/mmol), and CKD was 5.3%
(4.5 – 6.2%), 9.4% (8.4 – 10.5%), and 12.5% (11.4 – 13.8%)
respectively.
The prevalence of CKD and reduced eGFR was higher
in women compared to men, and increased with age
(Figure 2). The age standardized prevalence (95% CI) of
reduced eGFR (eGFRCKD-EPI(PK) <60.0 mL/min/1.73 m
2),
albuminuria (UACR ≥3 mg/mmol), and CKD was 7.4%
(6.2 – 8.6%), 11.1% (9.8 –12.4%), and 15.3% (13.7 – 16.9%)
respectively.
CKD determinants
Among the 2873 adults, a total of 359 (12.5%) had CKD.
These patients were significantly older, more likely to be
less physically active, have concomitant hypertension,
diabetes, coronary heart disease and stroke compared to
those without CKD (p < 0.05 for each).
Table 2 shows adjusted odds ratios and 95% CI of fac-
tors associated with CKD. The socio-demographic and
clinical factors independently associated with presence
Table 1 Socio-demographic and clinical characteristics of individuals with and without Chronic Kidney Disease
Characteristics Total (n = 2873) No CKD 2514 (87.4) CKD* 359 (12.5) P-value
Age in years, mean ± SD 51.5 ± 10.7 50.5 ± 10.0 58.8 ± 12.3 <0.001
Women, n (%) 1499 (52.2) 1299 (51.7) 200 (55.7) 0.152
Education, n (%)
No education 992 (34.5) 832 (33.1) 160 (44.6) <0.001
Primary & middle 929 (32.3) 813 (32.3) 116 (32.3)
Secondary & higher secondary 622 (21.6) 565 (22.5) 57 (15.9)
Graduate and above 330 (11.5) 304 (12.1) 26 (7.2)
Tobacco use, n (%)
Current users 1113 (38.7) 980 (39.0) 133 (37.0) 0.003
Past users 280 (9.7) 227 (9.0) 53 (14.8)
Never users 1480 (51.5) 1307 (52.0) 173 (48.2)
Employed in any occupation, n (%) 1209 (42.1) 1115 (44.4) 94 (26.2) <0.001
Physical Activity, METs < 840, n (%) 1725 (60.0) 1473 (58.6) 252 (70.2) <0.001
Hypertension, n (%)║§ 1267 (44.9) 1013 (41.0) 254 (72.2) <0.001
Diabetes Mellitus, n (%)† 615 (21.4) 465 (18.5) 150 (41.8) <0.001
History of CHD, n (%)†† 246 (8.6) 203 (8.1) 43 (12.0) 0.013
History of stroke, n (%) 88 (3.1) 59 (2.3) 29 (8.1) <0.001
Weight in Kg, mean ± SD 64.8 ± 14.4 65.0 ± 14.3 63.4 ± 14.6 0.063
Body mass index, mean ± SD║ 25.8 ± 5.5 25.8 ± 5.5 25.7 ± 5.1 0.767
Systolic BP, mean ± SD 137 ± 24 135 ± 22 153 ± 27 <0.001
Diastolic BP, mean ± SD 86 ± 13 85 ± 12 91 ± 15 <0.001
Fasting plasma glucose, mean ± SD‡ 6.4 ± 2.8 6.2 ± 2.6 7.7 ± 3.8 <0.001
Serum Cholesterol, mean ± SD‡ 4.9 ± 1.0 4.8 ± 1.0 5.0 ± 1.2 0.003
LDL, mean ± SD‡ 3.0 ± 0.8 3.0 ± 0.8 3.1 ± 1.0 0.087
HDL, mean ± SD‡ 1.0 ± 0.3 1.0 ± 0.3 1.1 ± 0.3 0.196
Triglycerides, mean ± SD‡ 1.8 ± 1.1 1.8 ± 1.1 2.0 ± 1.2 <0.001
eGFR, median (25th –75th percentiles) 92.8 (82.7 – 101.5) 94.6 (85.9 – 102.1) 68.2 (52.1 – 92.5) 0.001
UACR, median (25th –75th percentiles) 0.58 (0.38 – 1.07) 0.53 (0.36 – 0.83) 6.24 (3.46 – 19.60) <0.001
CKD = Chronic Kidney Disease; METs = Metabolic Equivalents; CHD = Coronary Heart Disease; BP = Blood Pressure; LDL = Low Density Lipoprotein cholesterol;
HDL = High Density Lipoprotein cholesterol; UACR = Urinary Albumin to Creatinine Ratio.
*CKD is defined as the eGFR < 60 mL/min/1.73 m2 estimated by CKD-EPIPK (0.686 × CKD-EPI
1.059) or urinary albumin to creatinine ratio (UACR) ≥3 mg/mmol.
║Missing observations: for hypertension status 50 were missing and for BMI 2 were missing.
§Hypertension was defined as persistent elevation of SBP ≥140 mm Hg or DBP ≥90 mm Hg on the basis of average of last two of three readings measured
5 minutes apart at each visit, on two separate occasions, or taking antihypertensive medications.
†Diabetes defined as fasting blood glucose ≥ 7.0 mmol/L or on anti-diabetic medications.
††CHD was defined as self-reported history of coronary heart disease.
‡Reported in SI units (mmol/L).
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SBP, raised fasting plasma glucose, raised triglycerides,
and history of stroke, (p < 0.05 for each)
CKD and hypertension
Among 359 individuals with CKD, 267 (74.4%, 95% CI:
69.5 – 78.8%) had concomitant hypertension using CKD
specific definition. About 48.7% (42.6 – 54.9%) of these
patients were on antihypertensive medications, and less
than 20% had their BP controlled to conventional target
of ≤140/90 mm Hg (Table 3). Beta blockers were the
single most commonly prescribed antihypertensiveagent (16.1%, 95% CI: 11.9 – 21.1), followed by various
combinations of antihypertensive medications (13.5%,
95% CI: 9.6 – 18.2). Only 9.7% (6.5 – 13.9%) were on
blockers of renin-angiotensin system alone whereas
16.9% (12.6 – 21.9%) patients were using these medica-
tions either as mono-therapy or in combination with
other antihypertensive drugs (Table 4).
Discussion
Our population based study is the first to report preva-
lence and factors associated with CKD from a South
Asian country using a locally validated eGFR equation.
Figure 1 eGFRCKD-EPI(PK) distribution by age in men and women. The lines have been plotted using quantile regression in Stata. The solid line
represent median eGFR and dashed lines represents 25th and 75th percentiles respectively. Abbreviation: eGFRCKD-EPI(PK), eGFR calculated by CKD-EPI
Pakistan (0.686 × CKD-EPI1.059).
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defined using validated eGFRCKD-EPI(PK) <60 mL/min/
1.73 m2, and/or albuminuria ≥3 mg/mmol or higher,
among adults aged 40 years or older in Karachi, Pakistan.
The prevalence of reduced eGFRCKD-EPI(PK) alone was
5.3% (4.5 – 6.2%). We found that CKD was independently
associated with older age, hypertension, diabetes, elevated
SBP, raised fasting plasma glucose, raised triglyceride
levels, and history of stroke (p < 0.05 for each). Despite
a high proportion of associated co-morbidities, CKD
remains under-treated with less than 10% and 20% of
patients had their BP controlled to targets of ≤130/80 mm
Hg, and ≤140/90 mm Hg, respectively per KDIGO 2012
Clinical Practice guidelines [8]. Our results of high pre-
valence of CKD underscore urgent need for efforts to
prioritize CKD on the public health agenda of Pakistan.
The distribution of eGFR in this population illustrate
an age related decline, (Figure 1) albeit with relatively
well persevered median eGFR among men and women
aged 60 years or older [13]. These findings underscorethe significance of low eGFR values which should prompt
further evaluation even in the elderly in this population.
The high prevalence of CKD is not surprising given
the high burden of major CKD risk factors in South
Asia. Hypertension and diabetes, both established risk
factors for end stage kidney disease, were independently
associated with CKD in this population [14,15]. Results
of national surveys indicate that hypertension and dia-
betes affect about 1 in 3 and 1 in 5 adults, respectively,
in Pakistan [16-18]. While, trends data on CKD are not
available, the 2010 Global Burden of Disease for Pakistan
reported a steep rise in the prevalence of major CKD
risk factors during the past two decades [6,19,20]. Our
finding of high prevalence of CKD is highly suggestive of
a parallel increase in the neglected burden of CKD in
Pakistan.
We observed that high triglyceride levels were independ-
ently associated with CKD. These findings are consistent
with those in the Western population demonstrating raised
triglycerides in individuals with CKD, [21] which in part
Figure 2 Age and sex specific crude prevalence of chronic kidney disease and reduced eGFR. The dark and light grey bars represent men
and women respectively. The prevalence percentages are plotted on y-axis and the age groups are plotted on the x-axis.
Table 2 Multivariable regression models for Chronic Kidney Disease
Characteristics Model 1*† Adjusted OR (95% CI) Model 2*‡ Adjusted OR (95% CI)
Age in years 1.35 (1.28 – 1.41) For each 05 year increase 1.31 (1.24 – 1.38) For each 05 year increase
Physical activity
< 840 METs 1.35 (1.04 – 1.75) -
≥ 840 METs 1.00
Hypertension
Hypertensive NA 1.90 (1.40 – 2.57)
Non-hypertensive 1.00
Diabetes mellitus
Diabetic NA 1.69 (1.18 – 2.43)
Non-diabetic 1.00
Systolic BP, mm Hg NA 1.15 (1.09 – 1.22) For each 10 mm Hg increase
Fasting plasma glucose, mmol/L NA 1.08 (1. – 1.13) For each 1 mmol/L increase
Triglycerides, mmol/L NA 1.07 (1.01 – 1.13) For each 0.5 mmol/L increase
History of stroke
Positive NA 1.73 (1.03 – 2.92)
Negative 1.00
NA = Not applicable; METs = Metabolic Equivalents; BP = Blood Pressure.
*Final sample size for multivariable models was 2823 and models are based on stepwise forward selection method.
†The candidate variables for model 1 include socio-demographic determinants only, i.e. age, gender, educational status, tobacco use and physical activity. The final
model was adjusted for clustering.
‡The candidate variables for model 2 include all socio-demographic and clinical variables, i.e. age, gender, educational status, tobacco use and physical activity,
hypertension status, diabetes status, history of CHD, history of stroke, body mass index, systolic BP, diastolic BP, fasting plasma glucose, serum cholesterol, low
density lipoprotein cholesterol, high density lipoprotein cholesterol, and total triglycerides. The final model was adjusted for clustering and history of coronary
heart disease.
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Table 3 Blood pressure control and use of antihypertensive medication among CKD patients with hypertension
according to level of UACR
Characteristics Overall, n
(%, 95% CIs)
UACR, mg/mmol, n (%, 95% CIs)
<3.0 ≥ 3.0 ≥3.0 and diabetes
n = 267 N = 56 N = 211 N = 107†
BP ≤ 140/90 mm Hg, n (%, 95% CI) 51 (19.1, 14.6 – 24.3) 13 (23.2, 13.0 – 36.4) 38 (18, 13.1 – 23.9) 20 (18.7, 11.8 – 27.4)
BP ≤ 130/80 mm Hg, n (%, 95% CI) 17 (6.4, 3.8 – 10.0) 6 (10.7, 4.0 – 21.9) 11 (5.2, 2.6 – 9.1) 6 (5.6, 2.1 – 11.8)
Use of antihypertensive medications, n (%, 95% CI) 130 (48.7, 42.6 – 54.9) 33 (58.9, 45.0 – 71.9) 97 (46, 39.1 – 52.9) 54 (50.5, 40.6 – 60.3)
UACR = Urinary Albumin to Creatinine Ratio; BP = Blood Pressure.
CKD (G3, A2 or worse) is defined as the eGFR < 60 mL/min/1.73 m2 estimated by CKD-EPIPK equation (0.686 × CKD-EPI
1.059) or UACR ≥3 mg/mmol.
†Patients with diabetes mellitus and UACR ≥3 mg/mmol along with CKD and hypertension.
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tients with CKD were more likely to have concomitant
stroke (adjusted OR, 95% CI: 1.73 (1.03 – 2.92). A number
of studies have established that both reduced eGFR and
urine albumin excretion, even in the high normal range,
predict a graded increase in cardiovascular morbidity [3].
Furthermore, the adverse environmental exposures includ-
ing high levels of ambient air pollutants and heavy metals
are likely to further enhance the CVD risk associated with
CKD in this population [22]. Although lead was phased
out of gasoline in Pakistan in 2002, the chronic exposure
would predispose this population to lead-related nephro-
toxicity especially in the presence of CKD, hypertension or
diabetes [23-25].
Recent trials data suggest benefit of lipid lowering on
CVD morbidity and mortality among patients with CKD
[26]. This practice needs to be integrated into CKD pre-
vention efforts in Pakistan.
We found that BP control was grossly sub-optimal
with less than 20% of patients having BP controlled to





Antihypertensive medications, mean ± SD 1.4 ± 0.8
ACEI/ARB only 26 (9.7, 6.5 –
ACEI/ARB only or in combination with others 45 (16.9, 12.6
Beta blockers only 43 (16.1, 11.9
Beta blockers only or in combination with others 64 (24.0, 19.0
Calcium channel blockers only 18 (6.7, 4.0 –
Calcium channel blockers only or in combination with others 40 (15.0, 10.9
Diuretics only 3 (1.1, 0.2 –
Diuretics only or in combination with others 19 (7.1, 4.3 –
Any combinations† 36 (13.5, 9.6 –
UACR = Urinary Albumin to Creatinine Ratio; ACEI/ARB = Angiotensin converting en
†Combination antihypertensive medications are based on various combinations of 2
the individual drug categories. Each individual drug refers to monotherapy.
‡Patients with diabetes mellitus and UACR ≥3 mg/mmol along with CKD and hyperKDIGO CKD Clinical Practice guidelines underscore
BP target of 130/80 mm Hg or less if the patient has
CKD with a higher degree of albuminuria (UACR ≥3 mg/
mmol) [8]. Clearly the vast majority of patients with CKD
failed to meet even the more relaxed target of ≤140/
90 mm Hg in Pakistan (Table 3). These findings call
for enhancing provider and patient education regard-
ing importance of BP control among patients with
CKD.
Evidence suggests benefit of antihypertensive therapy
and blockers of renin-angiotensin system are especially
protective in patients with CKD and albuminuria [27].
Strikingly, despite significant co-morbidities among
patients with CKD, only 48.3% (95% CI: 42.6 – 54.9%)
received antihypertensive medications. Moreover use
of blockers of renin-angiotensin system was grossly
inadequate with barely 17% of patients taking these
nephro-protective agents [28] (Table 4). Our results
highlight the sub-optimal delivery of CKD care in urban
Pakistan where private physicians are the dominant source
of service provision, and cost of medications is borne outamong CKD patients with hypertension according to
n
Is)
UACR, mg/mmol, n (%, 95% CIs)
<3.0 ≥3.0 ≥3.0 and diabetes
N = 56 N = 211 N = 107‡
1.4 ± 0.7 1.4 ± 0.8 1.5 ± 0.9
13.9) 7 (12.5, 5.2 – 24.1) 19 (9.0, 5.5 – 13.7) 10 (9.3, 4.6 – 16.5)
– 21.9) 12 (21.4, 11.6 – 34.4) 33 (15.6, 11–21.3) 20 (18.7, 11.8 – 27.4)
– 21.1) 9 (16.1, 7.6 – 28.3) 34 (16.1, 11.4 – 21.8) 13 (12.1, 6.6 – 19.9)
– 29.6) 15 (26.8, 15.8 – 40.3) 49 (23.2, 17.7 – 29.5) 22 (20.6, 13.4 – 29.5)
10.4) 4 (7.1, 2.0 – 17.3) 14 (6.6, 3.7 – 10.9) 10 (9.3, 4.6 – 16.5)
– 19.8) 9 (16.1, 7.6 – 28.3) 31 (14.7, 10.2 – 20.2) 21 (19.6, 12.6 – 28.4)
3.2) 2 (3.6, 0.4 – 12.3) 1 (0.5, 0.0 – 2.6) 1 (0.9, 0.0 – 5.1)
10.9) 6 (10.7, 4–21.9) 13 (6.2, 3.3 – 10.3) 12 (11.2, 5.9 – 18.8)
18.2) 10 (17.9, 8.9 – 30.4) 26 (12.3, 8.2 – 17.5) 18 (16.8, 10.3 – 25.3)
zyme inhibitor/Angiotensin receptor blocker.
or more above-mentioned anti-hypertensive drugs. They are not included in
tension.
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Pakistan identified serious deficiencies in knowledge and
management of hypertension [29]. The situation is likely
to be worse for CKD. Studies in the West have shown that
screening for CKD can improve BP control among
patients recognized to have CKD [30]. Thus, our findings
underscore implementation of KDIGO guidelines for
screening and management of CKD to be integrated
along with management of hypertension and diabetes in
the primary health infrastructure in Pakistan, coupled
with provider training and public education on aware-
ness of CKD. Appropriate referral mechanism need to
be established for those with advanced stages of CKD.
Such a model is likely to be cost-effective for prevention
of CKD in Pakistan.
Our study has limitations. First, the cross-sectional
design of the study does not permit conclusions regard-
ing causation, and reverse causal association of CKD
with BP, lipids, and other factors remains a possibility.
However, evidence on the importance of controlling
raised BP and glucose levels for slowing progression of
CKD is well established. Second, since the study was
conducted in Karachi, some variation in findings would
be expected in other urban and rural areas of Pakistan.
However, national survey indicates a high prevalence
of hypertension and diabetes across urban and rural
Pakistan [16]. Moreover, practices of providers in terms
of management of CKD risk factors, and provision of
health services in other areas of Pakistan are not better
than in Karachi [29]. Thus, prevalence of CKD is also
likely to be comparable and our findings generalizable.
Third, we relied on single measurement of serum cre-
atinine and UACR, whereas the clinical definition of
CKD requires persistent decrease in eGFR or elevation
in UACR for at least 3 months. However, single meas-
urement is considered appropriate for epidemiological
research, and has been used widely in other studies [31].
The study has several strengths. This is the first report
of prevalence of CKD using a validated eGFR equation
with a correction developed in the local South Asian
population. Moreover, IDMS (Isotope Dilution Mass
Spectrophotometry)-traceable serum creatinine, door to
door survey and representative population based on
census data of Karachi, and high response rate are the
main strength of this study. Thus, our findings would be
generalizable to the general population.
Conclusions
In summary, our findings are the first report of preva-
lence of CKD in Pakistan using a validated CKD-EPIPK
estimating equation (eGFRCKD-EPI(PK) <60 mL/min/1.73
m2), or albuminuria (UACR ≥3 mg/mmol). We found that
a high prevalence of CKD affecting 12.5% of adults aged
40 years or older. CKD was independently associated witholder age, hypertension, diabetes, raised systolic BP,
raised plasma fasting glucose, raised triglycerides, and
history of stroke. Less than 20% of patients with CKD
had BP controlled to conventional levels of ≤140/90
mm Hg. Our findings underscore the urgent need for
integrating CKD prevention efforts in the primary care
infrastructure in Pakistan, and possibly neighbouring
countries with high burden of CKD.Additional files
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